Almac Discovery Ltd. has nominated a new preclinical candidate molecule, ALM-401, a first-in-class bispecific antibody-drug conjugate (ADC) targeting EGFR/ROR1. It is being developed for the treatment of refractory lung cancer characterized by dual expression of ROR1 and EGFR.
Actym Therapeutics Inc. has obtained IND clearance from the FDA to begin a phase I trial of ACTM-838. The first-in-human study will enroll patients in the U.S. and Australia with advanced solid tumors who have failed prior lines of therapy and have no clinically beneficial treatment options.
Programmed cell death protein 1 (PD-1) is among the immune checkpoint molecules better explored in immunotherapy for cancer. However, it is necessary to obtain novel therapies where preclinical efficacy and safety data could translate into enhanced predictability of human efficacy, pharmacokinetics and side effects.
Georgiamune Inc. has gained FDA clearance for its IND application for GIM-531, a first-in-class oral regulatory T cell (Treg) inhibitor that enables the restoration of a strong immune response against cancer.
A group of scientists from Basel University Hospital have designed an antibody-drug conjugate (ADC) that eliminated blood cancer cells without attacking healthy hematopoietic stem cells (HSCs), which they modified by base editing and transplanted to renew an altered blood system. They achieved this by focusing on the panhematopoietic marker CD45.
Scientists at Hansoh Bio LLC, Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed antibody-drug conjugates (ADCs) comprising HER3 (erbB3)-targeting antibodies linked to a cytotoxic drug through a linker.
Bispecific T-cell-engaging antibodies have emerged as therapeutic options for the treatment of cancer, but limitations such as short half-life remain to be addressed. Researchers from Biontech SE reported the preclinical pharmacology and efficacy of BNT-142, a bispecific antibody targeting claudin-6 (CLDN6) and the T-cell marker CD3.
Merck Sharp & Dohme LLC has described antibody-drug conjugates (ADCs) comprising antibodies targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) linked to exatecan through a linker reported to be useful for the treatment of cancer.
RSS
